Key result
Interventricular septal thickness deviations are not independently associated with major cardiovascular events.
Why the study?
Localized thinning or thickening of the interventricular septum is a recognized morphologic feature of cardiac sarcoidosis, but the prognostic significance of interventricular septal thickness remained unclear.
Does deviation of interventricular septal thickness (IVST) from the normal reference range increase the risk of all-cause death, fatal ventricular arrhythmia events, or heart failure hospitalization in patients with cardiac sarcoidosis?
Observational (n=1,775)
Yes
Does deviation of interventricular septal thickness (IVST) from the normal reference range increase the risk of all-cause death, fatal ventricular arrhythmia events, or heart failure hospitalization in patients with cardiac sarcoidosis?
In patients with cardiac sarcoidosis, abnormal interventricular septal thickness (either thinning or thickening) at diagnosis is not independently associated with long-term adverse clinical outcomes after multivariable adjustment.
Abnormal IVST should not guide prognosis in cardiac sarcoidosis; leaves open whether septal morphology predicts outcomes in adjusted or prospective models.
Background Localized thinning or, in some cases, thickening of the interventricular septum has been recognized as a morphologic feature of cardiac sarcoidosis (CS). However, the prognostic significance of interventricular septal thickness (IVST) in patients with CS remains unclear. Purpose This study aimed to investigate the clinical implication of IVST in patients with CS. Methods This is a post-hoc analysis of a multicenter nationwide retrospective observational study, we analyzed patients diagnosed as CS and with available data for IVST measured at the time of diagnosis. Patients were stratified according to IVST into five groups at 2-mm intervals, centered on the median value of 9 mm, which also corresponds to the normal reference range: group 1 (≤ 6.0 mm), group 2 (6.1–8.0 mm), group 3 [reference] (8.1–10.0 mm), group 4 (10.1–12.0 mm), and group 5 (≥ 12.1 mm). The primary outcome was the composite outcome of all-cause death, fatal ventricular arrhythmia events, or heart failure hospitalization. Results In 1775 patients [64 (56-71) years old, 65.2% female], 454 primary outcomes were observed during the median follow-up period of 4.3 (2.4–6.5) years. The 5-year event rates of the primary outcome were 22.0%.Kaplan–Meier curves demonstrated higher incidences of primary outcome in IVST groups deviating from the reference group. The spline analysis indicated a J-curve–like association of IVST with the primary outcome. Although, in the univariable analysis, patients in group 1 and in the combined group 1 and 5 had a significant risk of the primary outcome than those in the other IVST groups (HR 1.46, 95%CI [1.12-1.89] and HR 1.38, 95%CI [1.11-1.71], respectively), no significant association with the primary outcome was observed for any of these groups in the multivariable analysis. Conclusions In patients with CS, there was no association with deviation of IVST and the risk of the composite of all-cause death, fatal ventricular arrhythmia events, or heart failure hospitalization after adjustment.
No takes yet. Share an insight, caveat, or question.
Takamura et al. (2026) conducted an observational in Cardiac sarcoidosis (n=1,775). Abnormal interventricular septal thickness (≤6.0 mm or ≥12.1 mm) vs. Reference interventricular septal thickness (8.1–10.0 mm) or other groups was evaluated on Composite of all-cause death, fatal ventricular arrhythmia events, or heart failure hospitalization (HR 1.46, 95% CI 1.12-1.89). Deviation in interventricular septal thickness showed a univariable risk (HR 1.46, 95% CI 1.12-1.89 for ≤6.0 mm), but was not associated with the primary composite outcome after adjustment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: